9 Followers on Owler

Forbion

Forbion Capital Partners provides investment for life sciences and biomedical technology firm. Read more

Sander Slootweg's photo - Managing Partner of Forbion

Managing Partner

Sander Slootweg

CEO Approval Rating

69/100

Founded:

2000

Status:

Investment CompanyIndependent Company

FORBION TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Ysios Capital is perceived as one of Forbion's biggest rivals. Ysios Capital was founded in 2008 in Donostia-San Sebastian, Barcelona. Ysios Capital is in the Investment Banking & Brokerage field.

Inveready is Forbion's #2 rival. Inveready is a Investment Company company that was founded in 2008 in Barcelona, Barcelona. Inveready competes in the Investment Management & Fund Operators industry. Compared to Forbion, Inveready has 212 fewer employees.

Sunstone Life Science Ventures A/S is one of Forbion's top competitors. Sunstone Life Science Ventures A/S's headquarters is in Copenhagen, Other, and was founded in 2007. Sunstone Life Science Ventures A/S operates in the Investment Banking & Brokerage industry. Sunstone Life Science Ventures A/S generates 226% of Forbion's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Northcap a competitor of Forbion?

Forbion Acquisitions

No recent acquisitions found related to Forbion

Forbion Funding History

Since Forbion was founded in 2000, it has participated in 10 rounds of funding. In total Forbion has raised $2.6B. Forbion's last funding round was on Apr 2021 for a total of $428.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Investment Fund
Apr 2021
$428M
-
Investment Fund
Dec 2020
$557.6M
-
Investment Fund
Jul 2020
$214.3M
-
Investment Fund
Jul 2020
$208M
Investment Fund
Sep 2018
$422.6M
-

Since Forbion was founded in 2000, it has participated in 10 rounds of funding. In total Forbion has raised $2.6B. Forbion's last funding round was on Apr 2021 for a total of $428.0M

Forbion Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

VectorY is a Netherlands-based biotechnology company that develops and commercializes gene therapies for the treatment of muscle and neurodegenerative disorders.
$37.6M
Jun 14, 2021
Seed
-
Numab is a Switzerland-based biopharmaceutical company that develops and commercializes immuno-oncology therapies for the treatment of cancer.
$110M
May 19, 2021
Series C
-
Gyroscope is a UK-based pharmaceutical company that researches and develops novel therapeutics for the treatment of eye disorders.
$148M
Mar 25, 2021
Series C
-
Amphista is a UK-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer.
$53M
Mar 15, 2021
Series B
-
Oxular is an England-based pharmaceutical company that develops and commercializes therapies for the treatment of retinal diseases.
$37M
Feb 28, 2021
Private Equity Round
-

Forbion News

April 21, 2021FierceBiotech

Forbion closes final European life sciences funding round at 360M with help from Eli Lilly

Forbion closes final European life sciences funding round at €360M with help from Eli Lilly badams Tu... See more »
March 26, 2021The Business Journals: Philadelphia

Gene therapy developer with U.S. operations in King of Prussia raises $148M in VC funding

The five-year-old company has now raised about $265 million over three funding rounds since its incep... See more »
March 26, 2021FinSMEs

Gyroscope Therapeutics Raises $148M in Series C Financing

Gyroscope Therapeutics Limited, a London, UK-based clinical-stage gene therapy company focused on tre... See more »
March 26, 2021Sharecast

Syncona invests 31m in Gyroscope

Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the reti... See more »
March 18, 2021Global University Venturing

News, Data and Events - Global University Venturing

Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is ... See more »

Forbion Press Releases

September 16, 2015BUSINESS WIRE

Amgen acquires Forbion portfolio company Dezima Pharma

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners ("Forbion"), one of the leading D... See more »
May 22, 2015PR NEWSWIRE

Fonds de solidarité FTQ Invests €10.5 Million in Forbion III to Attract International Life Science Funds to Québec

MONTRÉAL, May 22, 2015 /PRNewswire/ - In an effort to attract successful international life science f... See more »
January 26, 2015PR NEWSWIRE

enGene raises CAD 13.5 million (US$11.5M) to develop intestinal gene delivery platform

MONTRÉAL, Jan. 26, 2015 /CNW Telbec/ - enGene Inc., a Montréal-based biotechnology enterprise develop... See more »
January 26, 2015CNW

/C O R R E C T I O N from Source -- enGene; Fonds de solidarité FTQ; Lumira Capital/

In the news release, enGene raises CAD 13.5 million (US$11.5M) to develop intestinal gene delivery pl... See more »
October 2, 2014MARKETWIRED

Knight Therapeutics Inc. Expands Its Innovative Pharmaceutical Product Sourcing Strategy

MONTREAL, QUEBEC--(Marketwired - Oct. 2, 2014) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a lea... See more »
August 4, 2014BUSINESS WIRE

Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm invest... See more »
July 9, 2014BUSINESS WIRE

Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Announces Closing of Initial Public Offering of Po... See more »

Social Media

Forbion Headquarters

Gooimeer 2-35

Naarden, Flevoland1411

31-35-699-30-00

Driving Directions »

Trending Companies

Forbion Summary

ABOUT

Overview

Forbion Capital Partners provides investment for life sciences and biomedical technology firm. Forbion was founded in 2000. Forbion's headquarters is located in Naarden, Flevoland, NL 1411. It has raised 2.6B in 10 rounds. The latest round was in Apr ...

CEO

Forbion's Managing Partner, Sander Slootweg, currently has an approval rating of 69%. Forbion's primary competitors are Ysios Capital, Inveready & Sunstone Life Science Ventures A/S.

Frequently Asked Questions about Forbion

  1. When was Forbion founded?

    Forbion was founded in 2000
  2. Who is Forbion's CEO?

    Forbion's CEO is Sander Slootweg
  3. How much revenue does Forbion generate?

    Forbion generates $4.4M in revenue
  4. How much funding does Forbion have?

    Forbion has historically raised $2.6B in funding
  5. Where is Forbion's headquarters?

    Forbion's headquarters is in Naarden Flevoland, NL
  1. How many employees does Forbion have?

    Forbion has 244 employees
  2. What sector does Forbion operate in?

    Forbion is in Diversified Investment Services
  3. Who are Forbion's competitors?

    Forbion's top competitors are Ysios Capital, Inveready, Sunstone Life Science Ventures A/S
  4. Who has Forbion invested in?

    Forbion's has invested in companies such as VectorY, Numab, Gyroscope